title: Immunophenotypic transformation from acute undifferentiated leukemia to Burkitt's-like acute lymphoblastic leukemia.
abstract: Progression of more differentiated to less differentiated malignant phenotypes has been described infrequently during the natural evolution or at relapse of treated hematopoietic malignancies. This report describes an unusual instance of immunophenotypic transformation from an immunologically undifferentiated acute leukemia to a leukemia that at relapse possessed morphologic and immunologic markers characteristic of a Burkitt's-like acute lymphoblastic leukemia. A 26-year-old man initially presented with pancytopenia and a bone marrow diffusely replaced with blast cells morphologically most consistent with a French-American-British L2 subclassification. The surface immunophenotype of the blasts at diagnosis showed HLA-DR surface antigen but no myeloid, lymphoid, or immunoglobulin determinants. Despite successful induction and ongoing consolidation chemotherapy, the patient had a relapse five months after diagnosis; blast cells at relapse demonstrated marked cytoplasmic vacuolation consistent with a Burkitt's-like L3 acute lymphoblastic transformation. Immunophenotypic analysis revealed the presence of restricted immunoglobulin determinants (mu heavy chain and kappa light chain), as well as two separate B lineage surface determinants (BA-1 and B-1). Immunophenotypic transformations may reflect the presence of either a multiclonal or multipotent leukemic population; documentation of the frequency of such transformations and genomic analysis of the transformed subpopulations may be helpful in furthering the understanding of molecular mechanisms involved in leukemogenesis.
authors.forename: K B
authors.initials: KB
authors.lastname: Burck
authors.forename: L J
authors.initials: LJ
authors.lastname: Levitt
mesh_terms: D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D007945:Leukemia, Lymphoid / Q000276:immunology / Q000473:pathology*; D008297:Male; D010641:Phenotype